Vincerx Pharma FY2023 net loss $40.2M; cash $12.8M, runway into early Q3 2024

Vincerx Pharma, Inc.

Net loss for FY2023: $40.2M ($1.89/share) vs $63.0M ($3.00/share) in FY2022; Q4 2023 loss $4.9M ($0.23/share).
Cash and equivalents $12.8M as of Dec 31, 2023, down from $52.5M year-end 2022; expects runway into early Q3 2024.
R&D expenses fell to $29.0M in FY2023 from $49.8M in FY2022; G&A down to $13.6M from $18.9M.
Pipeline: VIP236 Phase 1 dose-escalation ongoing with 20 patients; VIP943 Phase 1 enrolling third cohort (9 patients dosed).
Enitociclib (CDK9 inhibitor) showed partial responses in PTCL and DLBCL combination studies with NIH.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vincerx Pharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 29, 2024, Vincerx Pharma, Inc. (the “Company”) issued a press release announcing financial results for its fiscal year ended December 31, 2023.

View on SEC.gov

325 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-082002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.